Document ID: D-2120
Matter ID: MAT-1120
Client: CL-1120
Document Type: Correspondence
Created: 28/11/2023
Uploaded By: Lina Gomez

---

Okay, here’s a draft of a short legal correspondence document for Pharmaceuticals International, addressing a regulatory inquiry. It aims for a professional and formal tone while conveying the key information.  Please remember this is a template and may need to be adjusted based on the specific details of the inquiry and the client's situation.

---

**[Your Law Firm Letterhead]**

**[Date]**

**[Regulatory Agency Name]**
**[Agency Address]**

**Subject: Response to Regulatory Inquiry Regarding [Specific Product/Process]**

Dear Sir/Madam,

This firm represents Pharmaceuticals International (“PI”) in response to your recent regulatory inquiry regarding [Specifically describe the inquiry - e.g., “the manufacturing and labeling of our product, ‘NovaX,” as outlined in your correspondence dated [Date of Agency Correspondence]”]. We acknowledge receipt of your formal request for clarification on [Briefly state the core issue, e.g., “the current GMP compliance standards for NovaX batch processing”]. PI has been diligently reviewing the relevant guidelines and regulations established by [Regulatory Agency Name] and is committed to ensuring full compliance with all applicable requirements. We understand the urgency of this inquiry and are providing this response to address your concerns as efficiently as possible.

PI’s operational practices for [Specific area of concern – e.g., ‘raw material sourcing’ or ‘quality control procedures’] are currently aligned with the stipulations outlined in [Relevant Regulation/Standard – e.g., 21 CFR Part 11] and [Other Relevant Regulation/Standard].  Specifically, we have implemented [Mention key steps PI has taken to demonstrate compliance – e.g., ‘routine audits’, ‘updated employee training’, ‘implementation of a new traceability system’]. We have retained a qualified compliance officer, [Officer’s Name and Title], to oversee this process and regularly monitor adherence to these regulations.  We are prepared to provide you with a comprehensive audit report documenting our adherence to these guidelines upon request.

We are confident that PI’s operational processes have been rigorously assessed and are currently operating within acceptable parameters.  To further demonstrate our commitment to transparency, we are formally requesting an opportunity to schedule a meeting with your team to discuss this matter in detail and address any further inquiries you may have. Please advise on the preferred method for scheduling this meeting.  We are dedicated to maintaining a robust and compliant operational environment and are readily available to cooperate fully with your review.

Sincerely,

[Your Name]
[Your Title]
Pharmaceuticals International
[Contact Information]

---

**Important Disclaimer:** *I am an AI Chatbot and not a legal professional. This document is a sample and should be reviewed and adapted by a qualified attorney to reflect the specific facts and circumstances of your case.  Legal advice should be sought before taking any action based on this document.*

To help me refine this further and make it even more useful, could you tell me:

*   What is the specific regulatory agency? (e.g., FDA, EMA, etc.)
*   What is the core issue of the inquiry? (A brief summary would be helpful.)
*   What is the specific product or process being investigated?